title: Induction and treatment of anergy in murine leprosy.
abstract: Leprosy is a disease consisting of a spectrum of clinical, bacteriological, histopathological and immunological manifestations. Tuberculoid leprosy is frequently recognized as the benign polar form of the disease, while lepromatous leprosy is regarded as the malignant form. The different forms of leprosy depend on the genetic and immunological characteristics of the patient and on the characteristics of the leprosy bacillus. The malignant manifestations of lepromatous leprosy result from the mycobacterial-specific anergy that develops in this form of the disease. Using murine leprosy as a model of anergy in this study, we first induced the development of anergy to Mycobacterium lepraemurium (MLM) in mice and then attempted to reverse it by the administration of dialysable leucocyte extracts (DLE) prepared from healthy (HLT), BCG-inoculated and MLM-inoculated mice. Mice inoculated with either MLM or BCG developed a robust cell-mediated immune response (CMI) that was temporary in the MLM-inoculated group and long-lasting in the BCG-inoculated group. DLE were prepared from the spleens of MLM- and BCG-inoculated mice at the peak of CMI. Independent MLM intradermally-inoculated groups were treated every other day with HLT-DLE, BCG-DLE or MLM-DLE, and the effect was documented for 98 days. DLE administered at a dose of 1.0 U (1 × 10(6) splenocytes) did not affect the evolution of leprosy, while DLE given at a dose of 0.1 U showed beneficial effects regardless of the DLE source. The dose but not the specificity of DLE was the determining factor for reversing anergy.
authors.affiliation: Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, México City, México.
authors.forename: Mario
authors.initials: M
authors.lastname: Juarez-Ortega
authors.forename: Víctor G
authors.initials: VG
authors.lastname: Hernandez
authors.forename: Patricia
authors.initials: P
authors.lastname: Arce-Paredes
authors.forename: Enrique B
authors.initials: EB
authors.lastname: Villanueva
authors.forename: Miguel
authors.initials: M
authors.lastname: Aguilar-Santelises
authors.forename: Oscar
authors.initials: O
authors.lastname: Rojas-Espinosa
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001500:BCG Vaccine / Q000276:immunology; D058491:Bacterial Load; D002457:Cell Extracts / Q000008:administration & dosage* / Q000276:immunology; D002478:Cells, Cultured; D017635:Clonal Anergy; D004195:Disease Models, Animal; D005260:Female; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods*; D015441:Leprosy, Tuberculoid / Q000097:blood / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008264:Macrophages / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D051379:Mice; D009167:Mycobacterium lepraemurium / Q000276:immunology* / Q000472:pathogenicity; D009569:Nitric Oxide / Q000378:metabolism; D012867:Skin / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D013997:Time Factors
chemical_list: D000907:Antibodies, Bacterial; D001500:BCG Vaccine; D002457:Cell Extracts; D009569:Nitric Oxide
keywords: BCG; Mycobacterium lepraemurium; anergy; leucocyte extracts; murine leprosy